Skip to main content

Treating the

root cause of

preeclampsia

and sustaining

pregnancy.

Learn More

Transforming the treatment of preeclampsia by harnessing Nobel prize-winning science.

Comanche is a biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Our purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining pregnancy. We envision a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective and sustainable.

Learn About Our WorkMeet Our Team

The
Problem

Learn More

The
Breakthrough

Learn More

The
Solution

Learn More

Patient and Survivor Resources

Read our latest news

January 17, 2024

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Read More

August 28, 2023

Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023

Read More

Contact Us

50 Beharrell St, Unit B
Concord, MA 01742

Contact Us

Comanche is a biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Our purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining pregnancy. We envision a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective and sustainable.

Sign up to receive email updates

Translate 🌎 💬